• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

byBryant LimandKiera Liblik
June 18, 2022
in Cardiology, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT-2i) use was associated with reduced risk of composite heart failure and all-cause mortality as compared to metformin.

2. Those in the SGLT-2i group had an increased incidence of genital infections during one-year follow-up.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recent clinical trials have demonstrated that there are cardioprotective benefits associated with SGLT-2i use. Accordingly, emerging guidelines recommend SGLT-2i as a first-line treatment for patients with type 2 diabetes and comorbid cardiovascular disease. However, the majority of trials have only evaluated SGLT-2i as a second-line treatment for diabetic patients. The present population-based cohort study used data from three healthcare databases in the United States to compare one-year cardiovascular outcomes in patients with type 2 diabetes prescribed either SGLT-2i or metformin. SGLT-2i initiators had significantly lower rates of composite all-cause mortality and incidence of hospitalization due to heart failure than metformin initiators. There were no significant differences in rates of adverse cardiovascular events between groups. The safety profile was similar between SGLT-2i or metformin initiators, other than a higher incidence of genital infections in the SGLT-2i group. A limitation of this study was the reliance on observational data, which diminished the ability to control for diabetes severity and socioeconomic parameters. The data also lacked representation of racially diverse participants, limiting the generalizability of study findings.

Click to read the study in AIM

Relevant Reading: Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

In-Depth [retrospective cohort]: The present study used data from three healthcare databases to compare cardiovascular and safety outcomes in patients with type 2 diabetes who were initiated on either SGLT-2i or metformin. The study cohort consisted of 8,613 SGLT-2i initiators and 17,226 metformin initiators, with a mean follow-up time of 10.7 (median 6.6) and 12.2 (median 7.3) months, respectively. The incidence of composite and individual cardiovascular outcomes was compared between SGLT2i and metformin initiators. The incidence rates per 1000 person-years for composite myocardial infarction, stroke, and all-cause mortality in the SGLT-2i group and the metformin group were 15.0 and 16.2, respectively (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.77 to 1.19). For composite hospitalization due to heart failure and all-cause mortality, incidence rates per 1000 person-years for those in the SGLT-2i group versus the metformin group were 18.3 and 23.5 (HR, 0.80; 95% CI, 0.66 to 0.97). There was no significant difference between groups for rates of stroke and all-cause mortality. The safety analysis, which included acute kidney injury, diabetic ketoacidosis, bone fractures, severe hypoglycemia, severe urinary tract infection, and lower-limb amputation, demonstrated no significant differences between the two groups other than higher incidences of genital infections in the SGLT-2i initiators (HR, 2.19; 95% CI, 1.91 to 2.51). Overall, the present study demonstrated that SGLT-2i may have cardioprotective effects as a first-line treatment for type 2 diabetes.

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

Unsweetened coffee consumption is associated with reduced risk of mortality

The DAPA-HF trial: Dapagliflozin in patients with heart failure [Classics Series]

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasemetforminSGLT-2 inhibitorstype 2 diabetes
Previous Post

No therapies for computer vision syndrome with high certainty evidence in meta-analysis

Next Post

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The DAPA-HF trial: Dapagliflozin in patients with heart failure [Classics Series]

June 10, 2022
Early language exposure is predictive of language skills and IQ in school-age children
Cardiology

Late and moderate preterm birth associated with increased cardiometabolic risk scores in young children

June 1, 2022
Next Post
Thalidomide may be effective in refractory pediatric Crohn’s disease

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.